Cell death induced by topoisomerase-targeted drugs: more questions than answers

被引:271
作者
Kaufmann, SH
机构
[1] Mayo Clin & Mayo Fdn, Div Oncol Res, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Grad Sch Med, Dept Pharmacol, Rochester, MN 55905 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION | 1998年 / 1400卷 / 1-3期
关键词
DNA topoisomerase; apoptosis; caspase; etoposide; camptothecin; topoisomerase; mutation; DNA repair; phosphatase;
D O I
10.1016/S0167-4781(98)00136-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chemotherapeutic agents that target topoisomerase I and II set into motion a series of biochemical changes that culminate in cell death, but only under some conditions. The realization that stabilization of covalent topoisomerase-DNA complexes is not sufficient to insure cell death has prompted investigators to examine various aspects of the drug-induced death process itself. Several discrete steps along this pathway have been identified, including (a) the processing of stabilized cleavage complexes into frank DNA strand breaks; (b) sensing of the DNA damage, leading to activation of stress-associated signaling pathways and cell cycle arrest; and (c) activation of a preexisting group of enzymes and enzyme precursors, typified by the cysteine-dependent aspartate-directed proteases (caspases), that catalyze the relatively orderly biochemical cascade of terminal events known as apoptosis. The present review discusses the evidence that these steps occur after treatment with etoposide or camptothecin, the two prototypic topoisomerase poisons that are commonly studied. As in any emerging area, a large numb er of questions remain to be answered ab out the process of cell death induced by topoisomerase-directed drugs. 0167-4781/98/$ - see front matter (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:195 / 211
页数:17
相关论文
共 186 条
[1]  
Adjei AA, 1998, CLIN CANCER RES, V4, P683
[2]   Selective induction of apoptosis in Hep 3B cells by topoisomerase I inhibitors: Evidence for a protease-dependent pathway that does not activate cysteine protease P32 [J].
Adjei, PN ;
Kaufmann, SH ;
Leung, WY ;
Mao, F ;
Gores, GJ .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (11) :2588-2596
[3]  
Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1
[4]   Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3 [J].
Amarante-Mendes, GP ;
Kim, CN ;
Liu, L ;
Huang, Y ;
Perkins, CL ;
Green, DR ;
Bhalla, K .
BLOOD, 1998, 91 (05) :1700-1705
[5]  
ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P233
[6]  
BACHUR NR, 1992, MOL PHARMACOL, V41, P993
[7]  
BAE YS, 1991, GENE, V101, P285
[8]  
Beere HM, 1996, MOL PHARMACOL, V49, P842
[9]   ETOPOSIDE (VP-16-213)-INDUCED GENE ALTERATIONS - POTENTIAL CONTRIBUTION TO CELL-DEATH [J].
BERGER, NA ;
CHATTERJEE, S ;
SCHMOTZER, JA ;
HELMS, SR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (19) :8740-8743
[10]   ACTIVATION OF POLY(ADP-RIBOSE)POLYMERASE IN APOPTOTIC HUMAN-CELLS [J].
BERNARDI, R ;
NEGRI, C ;
DONZELLI, M ;
GUANO, F ;
TORTI, M ;
PROSPERI, E ;
SCOVASSI, AI .
BIOCHIMIE, 1995, 77 (05) :378-384